No­var­tis re­thinks CML strat­e­gy for next-gen al­losteric drug due for a piv­otal read­out lat­er this year

In the lead­up to a “ma­jor ex­pect­ed” Phase III tri­al read­out for as­ci­minib in third-line chron­ic myel­oge­nous leukemia, No­var­tis has un­cer­e­mo­ni­ous­ly re­moved a planned fil­ing for the same drug as an ear­li­er line of ther­a­py — which is still be­ing test­ed in Phase II.

The Swiss phar­ma gi­ant gave the up­date on as­ci­minib, al­so dubbed ABL001, ex­act­ly one line in its 160-page pre­sen­ta­tion on Q4 and FY 2019 re­sults, along­side a dis­clo­sure that it’s dropped a Phase III for Ilaris (canakinum­ab) in hered­i­tary pe­ri­od­ic fevers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.